Neurotrophin delivery represents one of the most promising approaches for Parkinson's disease therapy, aiming to provide trophic support to vulnerable dopaminergic neurons in the substantia nigra pars compacta. The Glial Cell Line-Derived Neurotrophic Factor (GDNF) family—including GDNF, Neurturin (NRTN), Artemin (ARTN), and Persephin (PSPN)—has demonstrated potent neuroprotective effects on dopaminergic neurons in preclinical models. However, delivering these proteins to the central nervous system remains a significant challenge due to their inability to cross the blood-brain barrier and their short half-life in systemic circulation.
This page catalogs biotechnology and pharmaceutical companies developing therapies to deliver neurotrophic factors to the Parkinson's disease brain, including gene therapy approaches, cell-based delivery systems, protein engineering, and novel delivery technologies.
The neurotrophin delivery field for Parkinson's disease has evolved through several generations of technology:
Neurotrophin delivery represents one of the most promising approaches for Parkinson's disease therapy, aiming to provide trophic support to vulnerable dopaminergic neurons in the substantia nigra pars compacta. The Glial Cell Line-Derived Neurotrophic Factor (GDNF) family—including GDNF, Neurturin (NRTN), Artemin (ARTN), and Persephin (PSPN)—has demonstrated potent neuroprotective effects on dopaminergic neurons in preclinical models. However, delivering these proteins to the central nervous system remains a significant challenge due to their inability to cross the blood-brain barrier and their short half-life in systemic circulation.
This page catalogs biotechnology and pharmaceutical companies developing therapies to deliver neurotrophic factors to the Parkinson's disease brain, including gene therapy approaches, cell-based delivery systems, protein engineering, and novel delivery technologies.
The neurotrophin delivery field for Parkinson's disease has evolved through several generations of technology:
| Attribute | Value |
|-----------|-------|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |
uniQure has developed a proprietary AAV gene therapy platform and has applied it to various neurological indications. The company has explored GDNF delivery for Parkinson's disease through academic partnerships, leveraging their high-capacity AAV vector technology for sustained expression of neurotrophic factors in the striatum.
Technology Platform:
| Attribute | Value |
|-----------|-------|
| Headquarters | Cambridge, Massachusetts |
| Ticker | VYTR (NASDAQ) |
| Founded | 2013 |
| Focus | CNS gene therapy |
Voyager Therapeutics focuses on AAV-mediated gene therapy for neurological disorders. While their lead PD program (VY-AADC) delivers the AADC enzyme to restore dopamine synthesis, the company has explored additional targets for neuroprotection including approaches to support dopaminergic neuron survival.
Pipeline Relevance:
| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Founded | 2003 |
| Focus | AAV and lentiviral vectors |
ID Pharma is a Japanese biotechnology company specializing in viral vector development and manufacturing. The company has active programs in GDNF and Neurturin delivery for Parkinson's disease[@idpharma].
Programs:
| Program | Target | Stage | Description |
|---------|--------|-------|-------------|
| AAV-GDNF | Parkinson's disease | Preclinical | GDNF gene delivery to striatum |
| AAV-Neurturin | Parkinson's disease | Research | Neurturin expression for neuroprotection |
Capabilities:
| Attribute | Value |
|-----------|-------|
| Headquarters | New York, New York, USA |
| Ticker | BCLI (NASDAQ) |
| Founded | 2000 |
| Focus | Autologous MSC cell therapy |
BrainStorm's NurOwn® platform represents a cell-based approach to neurotrophin delivery. The therapy uses the patient's own bone marrow-derived mesenchymal stromal cells (MSCs) that are engineered to secrete elevated levels of neurotrophic factors including GDNF, BDNF, VEGF, and HGF[@brainstorm].
Technology:
| Program | Indication | Phase | Status |
|---------|------------|-------|--------|
| NurOwn | ALS | Phase 3 | Completed |
| NurOwn | Progressive MS | Phase 1 | Active |
| NurOwn | Alzheimer's disease | Preclinical | Planning |
| NurOwn | Parkinson's disease | Research | Exploratory |
Clinical Evidence:
| Attribute | Value |
|-----------|-------|
| Headquarters | Sydney, Australia |
| Ticker | LCT (ASX) |
| Founded | 2007 |
| Focus | Encapsulated cell therapy |
Living Cell Technologies developed NTCELL, an encapsulated cell therapy for Parkinson's disease that provides neurotrophic support through transplanted choroid plexus cells[@lct].
Technology:
| Trial | Phase | Status | Results |
|-------|-------|--------|---------|
| NTCELL-001 | Phase 1/2a | Completed | Primary endpoint met |
| NTCELL-002 | Phase 2b | Planned | Trial design in review |
Clinical Outcomes:
| Attribute | Value |
|-----------|-------|
| Focus | Cell therapy for CNS disorders |
Hope Biomedical has developed cell-based approaches for CNS delivery of therapeutic proteins. The company focuses on engineering cells to secrete neurotrophic factors for neurodegenerative disease applications.
| Attribute | Value |
|-----------|-------|
| Headquarters | Taipei, Taiwan / Boston, Massachusetts |
| Ticker | 6589 (TPEx) / PHCE (NASDAQ) |
| Founded | 2003 |
| Focus | Protein therapeutics |
PharmaEssentia has explored protein-based approaches to neurotrophin delivery, leveraging their protein engineering capabilities to develop stable, bioactive neurotrophic factor formulations.
Approach:
| Attribute | Value |
|-----------|-------|
| Headquarters | Emeryville, California |
| Ticker | FDMT (NASDAQ) |
| Founded | 2014 |
| Focus | AAV vector engineering |
4DMT develops next-generation AAV vectors with improved CNS tropism and delivery characteristics. While primarily a vector platform company, their technology enables partners to develop neurotrophin delivery programs.
Platform:
| Attribute | Value |
|-----------|-------|
| Headquarters | Rockville, Maryland |
| Ticker | RGNX (NASDAQ) |
| Founded | 2009 |
| Focus | AAV gene therapy |
REGENXBIO provides AAV vector technology through licensing and partnerships. Their NAV Technology Platform has been applied to various CNS programs, including neurotrophin delivery approaches.
Technology:
Cerevel Therapeutics (formerly part of Pfizer, now AbbVie) developed CERE-120 (AAV-NRTN), a gene therapy delivering neurturin to the Parkinson's disease brain. The program completed clinical trials:
| Technology | Advantages | Disadvantages | Stage |
|------------|------------|---------------|-------|
| AAV Gene Therapy | Sustained expression, single dose | Irreversible, immune response | Clinical |
| Cell Encapsulation | Retrievable, sustained release | Surgical implantation | Clinical |
| MSC Cell Therapy | Autologous, immune-privileged | Variable cell function | Clinical |
| Protein Infusion | Tunable dosing | Short half-life, BBB crossing | Historic |
| Exosomes/Nanoparticles | BBB crossing potential | Early stage | Preclinical |
| Factor | Primary Receptor | Target Neurons | Clinical Stage |
|--------|------------------|----------------|----------------|
| GDNF | GFRα1/RET | Dopaminergic, motor | Clinical |
| Neurturin | GFRα2/RET | Dopaminergic, sensory | Clinical (discontinued) |
| BDNF | TrkB | Multiple CNS neurons | Research |
| Artemin | GFRα3/RET | Sensory, sympathetic | Preclinical |
| Persephin | GFRα4/RET | Motor neurons | Preclinical |
| Company | Therapy | Identifier | Phase | Status |
|---------|---------|------------|-------|--------|
| BrainStorm | NurOwn | NCT03280056 | Phase 3 | Completed |
| LCT | NTCELL | ACTRN12615000216549 | Phase 1/2a | Completed |
| Various | AAV-GDNF | Various | Phase 1/2 | Various |
| Program | Company | Years | Outcome |
|---------|---------|-------|---------|
| Intracerebral GDNF | Various | 1999-2009 | Mixed results, side effects |
| CERE-120 (AAV-NRTN) | Cerevel/Pfizer | 2008-2019 | Phase 3 did not meet endpoint |
| AAV-GDNF (AAV2) | Various | 2010s | Ongoing |
| Company | Partner | Focus | Value |
|---------|---------|-------|-------|
| Voyager | NeuroPace | VY-AADC | Various |
| LCT | DIatherix | Development | Various |
| ID Pharma | Multiple | Vector manufacturing | Various |